

## Professor Dr. rer. nat. Antonia Zapf, Dipl. Stat. - Curriculum Vitae

<b>Current Position</b>	<b>Director (W3 Professor)</b> Institute of Medical Biometry and Epidemiology University Medical Center Hamburg-Eppendorf, Germany
<b>Education</b>	
2001 - 2006	Study of statistics (Diplom), Ludwig-Maximilians-University, Munich, Germany
<b>Qualifications</b>	
2016	Habilitation in Medical Biometry (Priv.-Doz.)
2012	Certificate of Medical Biometry of the German Region of the International Biometric Society (IBS-DR) and the German Society of Medical Informatics, Biometry, and Epidemiology (GMDS)
2009	PhD (Dr. rer. nat.)
2006	Diploma (Dipl. Stat.)
<b>Professional Positions</b>	
Since 2018	W3 full professorship and deputy director (since 2023 director), Institute of Medical Biometry, University Medical Center Hamburg-Eppendorf, Germany
2012 – 2018	Research assistant, Department of Medical Statistics at the University Medical Center Göttingen, Germany
2009 – 2012	Research assistant, Institute for Biometry, Hanover Medical School, Germany
2006 – 2009	Research assistant, Department of Medical Statistics at the University Medical Center Göttingen
<b>Research Interests</b>	
Statistical methods for diagnostic studies and clinical trials, adaptive designs, meta-analyses	
<b>Functions</b>	
Since 2022	Chair of the Medical Biometry section of the GMDS
Since 2022	Member of the Clinical Trials Expert Panel of the German Research Foundation (DFG)
Since 2021	Member of the scientific advisory board of the Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG)
Since 2020	Adjunct Professor at the University of Southern Denmark
Since 2020	Member of the Clinical Study Group of the German Centre for Cardiovascular Research (DZHK)
Since 2018	Member of the medical-scientific editorial board of Deutsches Ärzteblatt
2016 – 2020	Alternate member of the Commission for Paediatric Medicinal Products at the Federal Institute for Drugs and Medical Devices (BfArM)
<b>Current Third Party Funding as (Co-)PI</b>	
2024 – 2027	Evaluation of diagnostic tests for locally or temporally clustered data (ClusterDiag), funding of the DFG (ZA 687/12-1)
2023 – 2026	Development and evaluation of the effectiveness of an interactive e-learning program to improve the e-health literacy of cancer patients (eHK-Strong), funding of the DFG (ZA 687/11-1)

2022 – 2025	Long COVID: Psychological Risk Factors and Their Modification, funding of the DFG (ZA 687/8-1)
2022 – 2025	Missing values and estimands in diagnostic studies (MisEstiDiag), funding of the DFG (ZA 687/6-1)
2021 – 2025	FOR 5211: SOMACROSS - Persistent SOMAtic Symptoms ACROSS Diseases: From Risk Factors to Modification, Z-project, funding of the DFG (ZA 687/4-1)
2021 – 2025	Adaptive (seamless) designs for real-time evaluation of diagnostic tests and their usefulness for the parameterisation of dynamic infection spread models in epidemic and pandemic settings (EpiAdaptDiag), funding of the DFG (ZA 687/3-1)
<b>Selected Publications</b>	<p>Fierenz A, <u>Zapf A</u>. Current developments of the estimand concept. <b>Pharm Stat</b>. 2024 Apr 27. doi: 10.1002/pst.2395. Epub ahead of print.</p> <p>Kohlmann S, Sikorski F, König HH, Schütt M, <u>Zapf A</u>, Löwe B. The efficacy of automated feedback after internet-based depression screening (DISCOVER): an observer-masked, three-armed, randomised controlled trial in Germany. <b>Lancet Digit Health</b>. 2024 Jul;6(7):e446-e457.</p> <p><u>Zapf A</u>, Frömke C, Hardt J, Rücker G, Voeltz D, Hoyer A. Meta-Analysis of Diagnostic Accuracy Studies With Multiple Thresholds: Comparison of Approaches in a Simulation Study. <b>Biom J</b>. 2024 Oct;66(7):e202300101.</p> <p>Löwe B, Scherer M, Braunschneider LE, Marx G, Eisele M, Mallon T, Schneider A, Linde K, Allwang C, Joos S, Zipfel S, Schulz S, Rost L, Brenk-Franz K, Szecsenyi J, Nikendei C, Härter M, Gallinat J, König HH, Fierenz A, Vettorazzi E, <u>Zapf A</u>, Lehmann M, Kohlmann S. Clinical effectiveness of patient-targeted feedback following depression screening in general practice (GET.FEEDBACK.GP): an investigator-initiated, prospective, multicentre, three-arm, observer-blinded, randomised controlled trial in Germany. <b>Lancet Psychiatry</b>. 2024 Apr;11(4):262-273.</p> <p>Pepić A, Stark M, Friede T, Kopp-Schneider A, Calderazzo S, Reichert M, Wolf M, Wirth U, Schopf S, <u>Zapf A</u>. A diagnostic phase III/IV seamless design to investigate the diagnostic accuracy and clinical effectiveness using the example of HEDOS and HEDOS II. <b>Stat Methods Med Res</b>. 2024 Mar;33(3):433-448.</p> <p>Jensen M, Suling A, Metzner A, Schnabel RB, Borof K, Goette A, Haeusler KG, <u>Zapf A</u>, Wegscheider K, Fabritz L, Diener HC, Thomalla G, Kirchhof P. Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial. <b>Lancet Neurol</b>. 2023;22(1):45-54.</p> <p>Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N, Bertaglia E, Blomstrom Lundqvist C, Borlich M, Brandes A, Cabanelas N, Calvert M, Chlouverakis G, Dan GA, de Groot JR, Dichtl W, Kravchuk B, Lubiński A, Marijon E, Merkely B, Mont L, Ozga AK, Rajappan K, Sarkozy A, Scherr D, Sznajder R, Velchev V, Wichterle D, Sehner S, Simantirakis E, Lip GYH, Vardas P, Schotten U, <u>Zapf A</u>; NOAH-AFNET 6 Investigators; NOAH-AFNET6 sites and investigators. Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes. <b>N Engl J Med</b>. 2023 Sep 28;389(13):1167-1179.</p>